Get sample size updates by email

Receive educational sample size content

Get sample size updates by email

Receive great industry news once a week in your inbox

Get sample size updates by email

Receive educational sample size content

Get sample size updates by email

Receive great industry news once a week in your inbox

**Objective: **Our primary objective is to determine the clinical efficacy of PHiD-CV in reducing respiratory exacerbations in children aged 18 months to 14 years with recurrent PBB, CSLD or bronchiectasis.

**Year:** 2013

**Source:** Trials

**Link: **https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-282

**Clinical Area: **Respiratory

Sample Size Section in Paper/Protocol: |

“Prospective data collected in Brisbane children with non-CF bronchiectasis indicate a mean annual incidence of 2.1 (standard deviation 1.046) exacerbations requiring hospital clinic attendance or hospitalisation. PHiD-CV efficacy against exacerbations in children with bronchiectasis is unknown. However, based on the aforementioned pilot data and AOM data from the POET study (30% reduction) [33], our trial is powered to detect a 30% reduction from 2.1 to 1.47 exacerbations in the 12 months following the second vaccine dose. Assuming a Poisson distribution, 93 children per group will provide 90% power (α = 0.05, two-sided) to detect a 30% reduction in exacerbations in the PHiD-CV group and 80% power to detect a 25% reduction. Assuming a 10% loss to follow-up, we will recruit 206 children (103 per group). Differences of less than 20% are unlikely to change clinical practice without additional supporting evidence.” |

Summary of Necessary Parameter Estimates for Sample Size Calculation:

Parameter |
Value |

Significance Level (1-Sided) | 0.025 |

Control Group Rate | 2.1 |

Rate Ratio | 0.7 |

Exposure Time (years) | 1 |

Allocation Ratio | 1 |

Power | 90% |

Expected Dropout | 1% |

**Step 1: **

Select the **Test for the Ratio of Two Incidence Rates using the Poisson Model **from the Select Test Design & Goal window.

This can be done **using the radio buttons** or alternatively, you can** use the search bar** at the end of the Select Test Design & Goal window.

**Step 2:**Enter the parameter values for sample size calculation taken from the study protocol.

**Step 3:**Select Run to solve for sample size.

This gives a sample size of 93 per group, as per the study protocol. |

** **

**Step 4:**Once the calculation is completed, nQuery Advanced provides an output statement summarizing the results. It States:

Output Statement: |

In a study testing ratio of independent two incidence rates under a Poisson model rate, a sample of 93 subjects in group 1 observed for 1 time periods and a sample of 93 subjects in group 2 observed for 1 time periods achieves 90.14% power to detect an incidence rate ratio (γ₁/γ₀) of 0.7 (assuming the incidence rate ratio is 1 under the null hypothesis) when the mean incidence rate for group 1 is 2.1 at the 0.025 significance level using a one-sided test. This was done under the assumption that the test statistic would be the ln(CMLE). |

Commercial, academic &

government organizations

Recognized by the FDA, EMA

& other regulatory bodies

**Tags: **Agreement, Cardiology

#agreement, #cardiology

#agreement, #cardiology

#agreement, #oncology

#agreement, #urology

#agreement, #veterinary

#means, #cardiology

#means, #cardiology

#means, #immunology

#means, #nephrology

#means, #neurology

#means, #respiratory

#means, #respiratory

#means, #respiratory

#means, #respiratory

#means, #urology

#means, #urology

**Tags: **Proportions, Rheumatology

#proportions, #rheumatology

#proportions, #veterinary

#regression, #neurology

**Tags: **Survival Analysis, Cardiology

#survival, #cardiology

**Tags: **Survival Analysis, Oncology

#survival, #Oncology

#survival, #oncology

Copyright © Statsols 2020, All Rights Reserved. Privacy Policy